Markets:

Overview

News

Currencies

International

Treasuries

Novavax, Inc. - Common Stock (NQ:NVAX)

8.700 +0.280 (+3.33%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novavax, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

NOVAVAX INC (NASDAQ:NVAX) Surges on Q2 2025 Earnings Beat and FDA Approval for Nuvaxovid ↗

August 06, 2025

Novavax (NVAX) stock surges 5.5% pre-market after Q2 2025 earnings crush estimates with $239M revenue and $0.62 EPS, fueled by Sanofi deal and FDA approval for Nuvaxovid.

Via Chartmill

Topics Earnings

RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' ↗

August 06, 2025

The Department of Health and Human Services will cancel 22 vaccine development projects totaling $500 million.

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector ↗

August 01, 2025

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.

Via Benzinga

Novavax Announces Positive Preclinical Data From Bird Flu Vaccine: Retail Wonders When Will The Stock Be Fairly Valued ↗

July 24, 2025

Via Stocktwits

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates ↗

July 24, 2025

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies.

Via Benzinga

2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet ↗

July 11, 2025

Via The Motley Fool

Topics Cannabis

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months ↗

July 10, 2025

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 vaccine patent dispute.

Via Benzinga

Topics Intellectual Property

Medical Groups Sue RFK Jr. For Assault On Science Over Unlawful COVID-19 Vaccine Rollbacks ↗

July 08, 2025

Major health groups sue HHS and Robert F. Kennedy Jr. over COVID-19 vaccine policy changes for children and pregnant individuals.

Via Benzinga

Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma ↗

July 08, 2025

The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.

Via Stocktwits

RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval ↗

July 03, 2025

FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects.

Via Benzinga

CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm ↗

June 26, 2025

The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.

Via Stocktwits

Moderna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine Skeptics ↗

June 25, 2025

RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots.

Via Stocktwits

Why Is Cidara Therapeutics Stock Trading Higher On Monday? ↗

June 23, 2025

Cidara's CD388 met key goals in a Phase 2b flu trial, showing strong efficacy and safety data, with FDA talks planned for advancing to Phase 3.

Via Benzinga

This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

June 17, 2025

Via Benzinga

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal ↗

June 12, 2025

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.

Via Benzinga

RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Report ↗

June 12, 2025

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices.

Via Benzinga

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial ↗

June 11, 2025

Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 and older.

Via Benzinga

Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’ ↗

June 11, 2025

Both candidates were well tolerated, with nearly all adverse events identified as mild or moderate.

Via Stocktwits

American Pharmacists Association Withholds Endorsement Of CDC's Revised COVID-19 Vaccine Guidance ↗

June 10, 2025

The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule.

Via Benzinga

Vaccine Stocks Alert: Has RFK Jr.'s CDC Panel Shakeup Sent Retail Traders To The Sidelines? ↗

June 10, 2025

Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."

Via Stocktwits

Topics Government

Vaccine Stocks Moderna, Pfizer Hit After A Surprise Blow From RFK Jr. ↗

June 09, 2025

A CDC committee in charge of making vaccine recommendations was gutted Monday to make way for a new coalition.

Via Investor's Business Daily

Topics Government

RFK Jr. Champions 'Medical Freedom' While Curtailing Access, Say Public Health Experts ↗

June 06, 2025

U.S. Health Secretary Robert F. Kennedy Jr. has championed "medical freedom" while simultaneously limiting access to COVID-19 vaccines and restricting food stamp purchases, creating what public health...

Via Benzinga

Moderna's New COVID Vaccine Secures FDA-Clearance For Seniors, At-Risk Individuals ↗

June 02, 2025

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved efficacy and safety profile.

Via Benzinga

RFK Jr. Drops COVID Vaccine Recommendation For Healthy Kids, But Experts Warn Of Major Risks ↗

May 30, 2025

The U.S. Health and Human Services Secretary Robert F. Kennedy Jr. announced the Centers for Disease Control and Prevention will no longer recommend COVID-19 vaccines for healthy children and pregnant...

Via Benzinga

Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort ↗

May 29, 2025

The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation...

Via Benzinga

Topics Government

Robert F. Kennedy Jr. Says CDC Drops COVID Vaccine For 'Healthy' Pregnant Women, Children ↗

May 27, 2025

RFK Jr. says the COVID-19 vaccine is no longer on the CDC's recommended schedule for healthy kids and pregnant women, though the official site still shows it listed.

Via Benzinga

Analysts Think These Stocks Could More Than Double in Value

May 23, 2025

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Via MarketBeat

Topics World Trade

What's Driving the Market Sentiment Around Novavax? ↗

May 21, 2025

Via Benzinga

FDA Limits Annual COVID-19 Boosters To High-Risk Americans, Demands New Trials For Healthy Adults In Policy Shift Under RFK Jr. ↗

May 21, 2025

The U.S. Food and Drug Administration has announced significant changes to COVID-19 vaccine requirements, limiting annual booster approvals to older and high-risk Americans while implementing stricter...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

65 66 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novavax, Inc. - Common Stock (NQ:NVAX)

All News about Novavax, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today